Comparing Post-Op Narcotic Usage in Patients Receiving Periarticular Exparel vs. Standard Periarticular Joint Inj

• Status: Completed
• Trial end date: 2015-08-01
• Target enrollment: 0
• Participant gender: All

Summary

This study seeks to determine whether a new sustained-release local anesthetic solution (Exparel - Liposomal Bupivacaine) injected into the soft tissues around the joint after surgery will decrease opioid consumption and adverse events in opioid-tolerant patients presenting for total knee arthroplasty. The research hypothesis is that the Exparel (study) group will use less opioid in the first 48 hours post-operatively than the control group.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of California, Irvine
• Treatments: Bupivacaine; Narcotics

Criteria

Inclusion Criteria:

• Males and Females age 18+ years old having total knee arthroplasty at UCI

• Meet at least one of the following criteria "opioid tolerant":

• Taking 50mg oral morphine equivalent or more per day

• On long-acting opioids (fentanyl pathc, oxycontin, methadone, etc.)

• Being followed by a chronic pain physician

• All subjects must be free of renal or hepatic dysfunction; defined as:

• Glomerular filtration rate >60 mL/min/1.73m^2

• AST & ALT <150, total bilirubin <1.0, INR <1.3 (if not taking anticoagulants)

• No active hepatitis, no jaundice

Control group- received standard periarticular injection Research group- receives Exparel injection

Exclusion Criteria:

• Allergy to local Anesthetic

• Pregnancy

• Nursing mothers

• Children<18 years of age

• Renal impairment (GFR<60 mL/min/1.73 m^2

• Hepatic impairment (active hepatitis, elevated AST or ALT, jaundice)

• Any history of ventricular arrhythmia or supraventricular tachycardia, or myocardial infarction within the last six months.